ZA200701154B - Stable pegylated interferon formulation - Google Patents

Stable pegylated interferon formulation

Info

Publication number
ZA200701154B
ZA200701154B ZA200701154A ZA200701154A ZA200701154B ZA 200701154 B ZA200701154 B ZA 200701154B ZA 200701154 A ZA200701154 A ZA 200701154A ZA 200701154 A ZA200701154 A ZA 200701154A ZA 200701154 B ZA200701154 B ZA 200701154B
Authority
ZA
South Africa
Prior art keywords
pegylated interferon
formulations
interferon formulation
stable pegylated
stable
Prior art date
Application number
ZA200701154A
Other languages
English (en)
Inventor
Shameem Mohammed
Dabbara Anita
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200701154B publication Critical patent/ZA200701154B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200701154A 2004-08-12 2007-02-08 Stable pegylated interferon formulation ZA200701154B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60084604P 2004-08-12 2004-08-12

Publications (1)

Publication Number Publication Date
ZA200701154B true ZA200701154B (en) 2008-08-27

Family

ID=35885766

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701154A ZA200701154B (en) 2004-08-12 2007-02-08 Stable pegylated interferon formulation

Country Status (15)

Country Link
US (1) US7632491B2 (es)
EP (1) EP1796647B1 (es)
JP (1) JP4971160B2 (es)
KR (1) KR20070045244A (es)
CN (1) CN101039660B (es)
AT (1) ATE476967T1 (es)
AU (1) AU2005272862B2 (es)
BR (1) BRPI0513332A (es)
CA (1) CA2576549C (es)
DE (1) DE602005022895D1 (es)
ES (1) ES2349472T3 (es)
MX (1) MX2007001663A (es)
NO (1) NO20071341L (es)
WO (1) WO2006020720A2 (es)
ZA (1) ZA200701154B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
PL2097068T3 (pl) 2006-11-24 2013-12-31 Cadila Healthcare Ltd Preparaty koniugatów PEG-interferon alfa
EP2117514B1 (en) * 2007-03-05 2011-06-15 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
ES2968301T3 (es) * 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010064258A2 (en) * 2008-12-01 2010-06-10 Intas Biopharmaceuticals Limited Pharmaceutical formulations of interferon conjugates
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012118687A1 (en) * 2011-02-28 2012-09-07 Merck Sharp & Dohme Corp. Manually operated injector with restricted injection sequence
CA3024230C (en) 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
KR20150074167A (ko) * 2012-10-26 2015-07-01 루핀 리미티드 Peg 인터페론 알파-2b의 안정한 약학 조성물
HK1217633A1 (zh) * 2013-01-15 2017-01-20 Teva Pharmaceutical Industries Ltd. 冻乾方法
CN103054818B (zh) * 2013-01-28 2014-03-05 苏州二叶制药有限公司 一种优质高效的冷冻干燥技术
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
CN108379561B (zh) * 2018-03-01 2021-11-26 修正生物医药(杭州)研究院有限公司 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102562968B1 (ko) * 2018-11-01 2023-08-04 주식회사 셀비온 붕소 중성자 포획 치료용 파라-보로노페닐알라닌 조성물 및 이의 제조방법
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法
CA3194975A1 (en) * 2020-09-11 2022-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel or colloidal suspension derived from extracellular matrix, and uses thereof
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
CA2024046A1 (en) 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5691298A (en) * 1994-12-14 1997-11-25 The Procter & Gamble Company Ester oligomers suitable as soil release agents in detergent compositions
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en) * 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
WO2001012214A2 (en) * 1999-08-13 2001-02-22 F. Hoffmann-La Roche Ag MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法

Also Published As

Publication number Publication date
CA2576549C (en) 2011-01-18
EP1796647B1 (en) 2010-08-11
EP1796647A2 (en) 2007-06-20
US7632491B2 (en) 2009-12-15
CN101039660B (zh) 2010-10-06
ES2349472T3 (es) 2011-01-03
DE602005022895D1 (de) 2010-09-23
ATE476967T1 (de) 2010-08-15
CN101039660A (zh) 2007-09-19
AU2005272862B2 (en) 2011-03-10
KR20070045244A (ko) 2007-05-02
WO2006020720A3 (en) 2006-06-01
NO20071341L (no) 2007-03-12
BRPI0513332A (pt) 2008-05-06
JP4971160B2 (ja) 2012-07-11
AU2005272862A1 (en) 2006-02-23
HK1103977A1 (en) 2008-01-04
US20060051320A1 (en) 2006-03-09
CA2576549A1 (en) 2006-02-23
JP2008509919A (ja) 2008-04-03
MX2007001663A (es) 2007-04-10
WO2006020720A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
ZA200701154B (en) Stable pegylated interferon formulation
SG144075A1 (en) Protein stabilization formulations
DK1791532T3 (da) Sammensætning i mikropelletform med styret afgivelse af fysiologisk aktive stoffer, fremgangsmåde til deres fremstilling og anvendelse i den zootekniske sektor
WO2006096614A3 (en) Angiogenic heparin binding peptide amphiphiles
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MX2007005156A (es) Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas.
MY157683A (en) Combination product for controlling parasites on animals
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2005112633A3 (en) Compounds and compositions for delivering active agents
ZA201002812B (en) Parathyroid hormone formulations and uses thereof
TW200614987A (en) Novel compounds
WO2010127142A3 (en) Use of lignosulfonates in suspo-emulsions for producing pesticide compositions
EP1748703A4 (en) TASTE MATRIX COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR THE APPLICATION THEREOF, AND FOODS MANUFACTURED THEREFROM
PH12016501877A1 (en) Lypophilized factor ix formulations
WO2005048731A3 (en) Lecithin-containing granular compositions and methods of their preparation
TW200630118A (en) Stabilized freeze-dried formulation for cephalosporin derivatives
MY153391A (en) Composition for controlling parasites on animals
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
EP1828305A4 (en) LOW LOSS PREIMPREGNE, COMPOSITIONS USEFUL FOR ITS PREPARATION AND USES THEREOF
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
MEP0708A (xx) Dobijanje gama-aminokisjelina sa afinitetom za alfa-delta protein
NO20065791L (no) Asyklovir-formuleringer
WO2005062874A3 (en) Compounds and compositions for delivering active agents
WO2005105832A3 (en) Biologically active peptide vapeehptllteaplnpk derivatives